查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386413

肺部药物输送市场报告：2030 年趋势、预测与竞争分析

Pulmonary Drug Delivery Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

肺部药物输送的趋势和预测

预计到 2030 年，全球肺部药物输送市场将达到 681 亿美元，2024 年至 2030 年年复合成长率为 2.5%。这个市场的主要驱动因素是呼吸系统疾病盛行率的上升、人们对肺部药物输送益处的认识不断提高以及对居家医疗服务的需求不断增加。全球肺部药物输送市场的未来被认为是充满希望的，医院/诊所市场和居家医疗市场都有商机。

肺部药物输送市场洞察

Lucintel 预测，由于呼吸系统疾病的盛行率不断增加以及慢性慢性阻塞性肺病肺病治疗的有利报销政策，慢性阻塞性慢性阻塞性肺病(COPD) 在预测期内仍将是最大的细分市场。

在这个市场中，随着全球医院药局数量的不断增加，医院和诊所将继续成为一个重要的细分市场。

由于其先进的医疗保健系统，北美将继续成为最大的地区，为患者提供最新的肺部药物输送设备和治疗方法。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 哪个产业将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球肺部药物输送市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球肺部药物输送市场趋势（2018-2023）与预测（2024-2030）
  • 全球肺部药物输送市场（按应用）
    • 气喘
    • 慢性阻塞性肺病
    • 过敏性鼻炎
    • 囊肿纤维化
    • 其他的
  • 按最终用途分類的全球肺部药物输送市场
    • 医院和诊所
    • 居家照护
  • 按配销通路的全球肺部药物输送市场
    • 医院药房
    • 零售药房
    • 电子商务

第4章2018-2030年分地区市场趋势及预测分析

  • 全球肺部药物输送市场区域分布
  • 北美肺部药物输送市场
  • 欧洲肺部药物输送市场
  • 亚太肺部药物输送市场
  • 其他区域性肺部药物输送市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球肺部药物输送市场成长机会（按应用）
    • 全球肺部药物输送市场最终用途的成长机会
    • 按配销通路的全球肺部药物输送市场成长机会
    • 按地区分類的全球肺部药物输送市场成长机会
  • 全球肺部药物输送市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球肺部药物输送市场的产能
    • 全球肺部药物输送市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • GlaxoSmithKline
  • 3M Company
  • Koninklijke Philips
  • AstraZeneca
  • Boehringer Ingelheim
简介目录

Pulmonary Drug Delivery Trends and Forecast

The future of the global pulmonary drug delivery market looks promising with opportunities in the hospitals & clinic and home care markets. The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2030 with a CAGR of 2.5% from 2024 to 2030. The major drivers for this market are rising prevalence of respiratory diseases, growing awareness towards the benefits of pulmonary drug delivery, and increasing demand for home-based healthcare services.

A more than 150-page report is developed to help in your business decisions.

Pulmonary Drug Delivery by Segment

The study includes a forecast for the global pulmonary drug delivery by application, end use, distribution channel, and region.

Pulmonary Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Cystic Fibrosis
  • Others

Pulmonary Drug Delivery Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Home Care

Pulmonary Drug Delivery Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Pulmonary Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Pulmonary Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pulmonary drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pulmonary drug delivery companies profiled in this report include-

  • Glaxosmithkline
  • 3M Company
  • Koninklijke Philips
  • Astrazeneca
  • Boehringer Ingelheim

Pulmonary Drug Delivery Market Insights

Lucintel forecasts that chronic obstructive pulmonary disease (COPD) will remain the largest segment over the forecast period due to increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

Within this market, hospitals & clinics will remain the larger segment due to growing number of hospital pharmacies across the globe.

North America will remain the largest region due to advanced healthcare system, which provides patients with access to the latest pulmonary drug delivery devices and treatments.

Features of the Global Pulmonary Drug Delivery Market

Market Size Estimates: Pulmonary drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pulmonary drug delivery market size by application, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: Pulmonary drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different applications, end uses, distribution channels, and regions for the pulmonary drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pulmonary drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the pulmonary drug delivery market size?

Answer: The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2030.

Q.2 What is the growth forecast for pulmonary drug delivery market?

Answer: The global pulmonary drug delivery market is expected to grow with a CAGR of 2.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the pulmonary drug delivery market?

Answer: The major drivers for this market are rising prevalence of respiratory diseases, growing awareness towards the benefits of pulmonary drug delivery, and increasing demand for home-based healthcare services.

Q4. What are the major segments for pulmonary drug delivery market?

Answer: The future of the pulmonary drug delivery market looks promising with opportunities in the hospitals & clinic and home care markets.

Q5. Who are the key pulmonary drug delivery market companies?

Answer: Some of the key pulmonary drug delivery companies are as follows:

  • Glaxosmithkline
  • 3M Company
  • Koninklijke Philips
  • Astrazeneca
  • Boehringer Ingelheim

Q6. Which pulmonary drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that chronic obstructive pulmonary disease (COPD) will remain the largest segment over the forecast period due to increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

Q7. In pulmonary drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to advanced healthcare system, which provides patients with access to the latest pulmonary drug delivery devices and treatments.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the pulmonary drug delivery market by application (asthma, chronic obstructive pulmonary disease, allergic rhinitis, cystic fibrosis, and others), end use (hospitals & clinics and home care), distribution channel (hospital pharmacies, retail pharmacies, and e-commerce), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pulmonary Drug Delivery Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Pulmonary Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Pulmonary Drug Delivery Market by Application
    • 3.3.1: Asthma
    • 3.3.2: Chronic Obstructive Pulmonary Disease
    • 3.3.3: Allergic Rhinitis
    • 3.3.4: Cystic Fibrosis
    • 3.3.5: Others
  • 3.4: Global Pulmonary Drug Delivery Market by End Use
    • 3.4.1: Hospitals & Clinics
    • 3.4.2: Home Care
  • 3.5: Global Pulmonary Drug Delivery Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: E-commerce

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Pulmonary Drug Delivery Market by Region
  • 4.2: North American Pulmonary Drug Delivery Market
    • 4.2.2: North American Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
  • 4.3: European Pulmonary Drug Delivery Market
    • 4.3.1: European Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
    • 4.3.2: European Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
  • 4.4: APAC Pulmonary Drug Delivery Market
    • 4.4.1: APAC Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
    • 4.4.2: APAC Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
  • 4.5: ROW Pulmonary Drug Delivery Market
    • 4.5.1: ROW Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
    • 4.5.2: ROW Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Application
    • 6.1.2: Growth Opportunities for the Global Pulmonary Drug Delivery Market by End Use
    • 6.1.3: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Region
  • 6.2: Emerging Trends in the Global Pulmonary Drug Delivery Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Pulmonary Drug Delivery Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pulmonary Drug Delivery Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GlaxoSmithKline
  • 7.2: 3M Company
  • 7.3: Koninklijke Philips
  • 7.4: AstraZeneca
  • 7.5: Boehringer Ingelheim